KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-cash Items (2018 - 2020)

Historic Non-cash Items for Esperion Therapeutics (ESPR) over the last 3 years, with Q2 2020 value amounting to $72.4 million.

  • Esperion Therapeutics' Non-cash Items rose 223734.31% to $72.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $72.4 million, marking a year-over-year increase of 223734.31%. This contributed to the annual value of $109.1 million for FY2019, which is 370452.47% up from last year.
  • According to the latest figures from Q2 2020, Esperion Therapeutics' Non-cash Items is $72.4 million, which was up 223734.31% from $3.2 million recorded in Q1 2020.
  • Over the past 5 years, Esperion Therapeutics' Non-cash Items peaked at $109.1 million during Q4 2019, and registered a low of $2.3 million during Q1 2018.
  • Over the past 3 years, Esperion Therapeutics' median Non-cash Items value was $24.3 million (recorded in 2019), while the average stood at $40.3 million.
  • Per our database at Business Quant, Esperion Therapeutics' Non-cash Items tumbled by 4230.05% in 2019 and then soared by 223734.31% in 2020.
  • Quarter analysis of 3 years shows Esperion Therapeutics' Non-cash Items stood at $83.5 million in 2018, then surged by 30.65% to $109.1 million in 2019, then plummeted by 33.61% to $72.4 million in 2020.
  • Its Non-cash Items was $72.4 million in Q2 2020, compared to $3.2 million in Q1 2020 and $109.1 million in Q4 2019.